Numerion Labs vs Schrödinger (2026)

AI Health Index verifiedSeptember 28, 2026
Verdict

Numerion Labs, the company formerly called Atomwise, and Schrödinger both built structure based methods for finding small molecules, and they now operate differently. Numerion develops its own small molecules for immune and inflammatory disease on three components: COSMOS, a chemistry foundation model; APEX, an enumerator described as evaluating ten billion virtual compounds in under 30 seconds; and EXPO, which optimizes binders into candidates. Schrödinger licenses physics based simulation software to pharmaceutical, biotechnology and academic teams, and runs a pipeline of its own on the same platform. Numerion's strongest published evidence is from its Atomwise years: the AIMS study found structurally novel hits for 235 of 318 targets nominated by academic laboratories. Schrödinger offers software a team runs itself.

The case for Numerion Labs
  • A prospective published screening record: novel hits for 235 of 318 academic targets in the AIMS study (Scientific Reports, 2024).
  • A current platform of COSMOS, APEX and EXPO, aimed at immune and inflammatory disease.
  • Enumeration at scale, described in October 2025 research with NVIDIA.
The case for Schrödinger
  • Software licensed directly, so a team runs its own programs without a partnership.
  • Physics based methods such as Glide docking and FEP+ binding affinity, paired with machine learning.
  • An enterprise design environment, LiveDesign, for collaborative work across a discovery team.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Numerion Labs and Schrödinger are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact Numerion Labs Schrödinger
Primary category Drug Discovery AI Drug Discovery AI
Headquarters San Francisco, CA New York, NY
Website numerionlabs.ai schrodinger.com
Attribute Matrix

Side by Side

Select any grade to read the note behind it.

Axis
N
Numerion Labs
S
Schrödinger
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each vendor in one paragraph

Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.

Numerion Labs

Numerion Labs, formerly known as Atomwise, is a San Francisco AI drug discovery company developing small molecules for immune and inflammatory disease, led by chief executive Steve Worland.

Source: AI Health Index, September 2026

Schrödinger

Computational chemistry software company (Nasdaq: SDGR) whose physics based molecular simulation platform is licensed to pharmaceutical, biotechnology, industrial and academic organizations, alongside a proprietary therapeutics pipeline built on the same platform.

Source: AI Health Index, September 2026

FAQ

Questions buyers ask

How do Numerion Labs and Schrödinger handle patient data?

For Numerion Labs, the sensitive material is a partner's own targets, compound data and assay results, the project data EXPO adapts its models to.

With Schrödinger, patient data does not enter the platform; the company's separate clinical trial policy covers participants in its own trials. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.

How much do Numerion Labs and Schrödinger leave to the clinician?

In Numerion Labs' case, the picks were then screened in the laboratory: by the academic collaborators in the AIMS program, and, for internal programs, at contract research organizations after synthesis at Enamine. On the current platform, EXPO optimization algorithms carry novel binders toward drug candidates, and the chief executive describes APEX as letting chemist and computer work together in real time.

For Schrödinger, the decision to make a molecule stays with the customer's scientists. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.

Disclosure

Both records were reviewed on this site in September 2026. Atomwise's published results predate the rename, and Numerion's current platform has less published behind it than the AtomNet work did.

Ask both which of their published results were produced by the version of the platform you would be using.